Subcapsular Hematoma of The Liver Revealing RENDU-OSLER Disease: About A Pediatric Case
DOI:
https://doi.org/10.14738/bjhmr.103.14745Abstract
RENDU-OSLER's disease is a rare hereditary disease of autosomal dominant transmission, it is a condition characterized by mucocutaneous and visceral telangiectasias; often revealed by recurrent epistaxis, hemostasis can be difficult. We report the observation of a 10-year-old girl who presented with chronic abdominal pain secondary to a subcapsular hematoma of the liver due to the rupture of an arteriovenous malformation falling within the framework of RENDU- OSLER
References
C. fagnouRendu–Osler disease in children Hereditary hemorrhagic telangiectasia in children Volume 4, Issue 3, September 2021
Maaloul, I.; Aloulou, H.; Fourati, H.; Sfaihi, L.; Chabchoub, I.; Kamoun, T.; Mnif, Z.; Hachicha, M. (2014). Rendu-Osler-Weber disease: about a new pediatric observation. Archives of Pediatrics, 21(7), 768–771.doi: 10.1016/j.arcped.2014.04.021
Plauchu H, de Chadarevian JP, Bideau A, et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32:291–7
Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24:203–19
V. Cottin, A.-S. Blanchet, J.-F. Cordier; Pulmonary Vascular Manifestations of Rendu-Osler Disease: Screening, Diagnosis and Treatment Pneumology Department, Reference Center for Orphan Pulmonary Diseases, Louis Pradel Hospital, Lyon I University, Rendu-Osler Disease Research Network, UMR 754, IFR 128 Lyon, France Khayi, F. Z., ElBaz, M., & ElHoudzi, J. (2023). Subcapsular Hematoma of The Liver Revealing RENDU-OSLER Disease: About A Pediatric Case. British Journal of Healthcare and Medical Research, Vol - 10(3). 156-159.
Zalagh, M.; Errami, N.; Bouaity, B.; Hemmaoui, B.; Itoua, W.; Benariba, F. (2011). Severe epistaxis from Rendu-Osler-Weber disease. Journal of Stomatology and Maxillofacial Surgery, 112(5), 310–312.doi: 10.1016/j.stomax.2011.08.016
Guidelines of the French Society of Otorhinolaryngology (SFORL) (short version). Specific treatment of epistaxis in Rendu-Osler-Weber disease L.Robard, J. Michel, V. Prulière Escabasse, E. Bequignon, B. Vérillaud, O. Malard, L. Crampette, The SFORL Work-Group, O. Malard, L. Crampette, M. Achache, MY Alaoui Lamrani , L. Ardillon, E. Babin, C. Bal Dit Sollier, E. Bequignon, M. Borsik, L. Castillo, A. Coste, C. Debry, P. Dessi, L. Drouet, X. Dufour, S. Dupuis-Girod, F. Faure, P. Gallet, R. Guldman, E. Houdart, R. Jankowski, F. Jegoux, S. Leble, J. Michel, G. Mortuaire, E. Mouchon, C. Page, V. Pruliere Escabasse, L. Robard, A. Roux, JP Saint Maurice, G. Sarlon, V. Strunski, V. Trevillot, B. Verillaud, P. Vironneau
gaillard s, dupuis-girod s, Boutitie f, et al. tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a european cross-over controlled trial in a rare disease. J thromb haemost 2014; 12:1494-502.
chen st, karnezis t, davidson tm. Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. laryngoscope 2011; 121:644-6.
Liver damage in Rendu-Osler disease: about a case and review of the literature Hanen Loukil,Mouna Snoussi,Hela Fourati,Faten Frikha,Raida Ben Salah,Moez Jallouli,Sameh Marzouk,Zeineb Mnif, AndZouhir Bahloul
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 F Z. Khayi, M. ElBaz, J. ElHoudzi
This work is licensed under a Creative Commons Attribution 4.0 International License.
